Pfizer Loses $43 Billion of Market Value!
Shares of Pfizer Inc. suffered their biggest monthly decline since 2009 in January
As investors anticipated a troubled path ahead for the drugmaker’s Covid products.
Tweet on Pfizer stock
Shares of @pfizer suffered their biggest monthly decline since 2009!
As investors anticipated a troubled path ahead for the drugmaker’s Covid products.#pfizer #stocks pic.twitter.com/lJnAi5psWf— The_Journalbiz (@the_journalbiz) January 31, 2023
Bloomberg Chart on Pfizer stock
The stock has slumped 15% this month, erasing $43 billion in market value. In its earnings report on Tuesday,
Pfizer presented a weaker-than-estimated sales outlook for its Covid vaccine and pill, and its shares fluctuated.
“PFE was already widely expected to guide below consensus – and the ’23 guide delivered on that,” Barclays analyst Carter Gould, who has a hold-equivalent rating on the stock, wrote in a note. Given the stock’s decline so far this month, “there had been hope for a bounce once the print was out of the way, however, we’re skeptical that will materialize in the near term.”
- Pfizer’s shares got a boost throughout the pandemic as its Covid-19 vaccine and pill brought in billions of dollars in sales.
The 2023 guidance miss was “widely anticipated” and was the reason shares had been weak heading into the report, Cantor Fitzgerald analyst Louise Chen, who holds a buy-equivalent rating on the stock, wrote in a note
